Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-736-1 | CAS number: 865-33-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The abiotic hydrolysis of potassium methanolate with tissue water results in the formation of potassium ions, hydroxide ions and methanol. Exposure to non-irritant levels of potassium methanolate via the dermal or inhalation route is not expected to lead to relevant uptake of the ionic degradation products potassium ions or hydroxide ions in amounts that would exceed the normal physiological levels. Potassium ions are normal constituents of body fluids. Potassium ions play an essential role in human physiology, but starts to be toxic at plasma concentrations exceeding 200 - 250 mg/L. Its concentration in blood is regulated principally by renal excretion/re-absorption and controlled by an effective feed-back autoregulation system. A systemic intoxication by potassium methanolate is therefore not expected. Exposure to hydroxide ions from sodium methanolate exposure could potentially increase the pH of the blood and lead to alkalosis. However, the pH of the blood is regulated between narrow ranges (pH 7.0 to 7.8) and an excessive pH of the blood is prevented by the bicarbonate buffer system, respiration and renal compensation mechanisms. The hydrolysis product methanol is fast absorbed and metabolised, so that no bioaccumulation is expected.
Key value for chemical safety assessment
Additional information
According to the OECD SIDS for sodium and potassium methanolate (OECD, 2006), the abiotic hydrolysis of potassium methanolate under aqueous conditions results in the formation of potassium ions, hydroxide ions and methanol. Information on the toxicokinetics, metabolism and distribution data of potassium hydroxide and methanol can be found in the respective OECD SIDS dossiers (OECD, 2002; OECD, 2004).
Exposure to non-irritant levels of potassium methanolate via the dermal or inhalation route is not expected to lead to relevant uptake of the ionic degradation products potassium ions or hydroxide ions in amounts that would exceed the normal physiological levels.
Exposure to hydroxide ions from potassium methanolate exposure could potentially increase the pH of the blood and lead to alkalosis. However, the pH of the blood is regulated between narrow ranges (pH 7.0 to 7.8) and an excessive pH of the blood is prevented by the bicarbonate buffer system, respiration and renal compensation mechanisms (European Commission, 2007; OECD, 2002).
Potassium ions are normal constituents of body fluids. K+plays an essential role in human physiology, but starts to be toxic at plasma concentrations exceeding 200 - 250 mg/L. Its concentration in blood is regulated principally by renal excretion/re-absorption and controlled by an effective feed-back autoregulation system (OECD, 2002). A systemic intoxication by potassium methanolate is not expected. For potassium hydroxide, SIAM 13 concluded: "Under normal handling and use conditions (non-irritating) neither the concentration of potassium in the blood nor the pH of the blood will be increased above normal limits and therefore KOH is not expected to cause systemically toxic levels in the blood. The renal excretion of K+can be elevated and the OH¯ ion is neutralised by the bicarbonate buffer system in the blood." (OECD 2002, OECD 2006)
According to the OECD SIDS for methanol (OECD, 2004), methanol is readily absorbed by inhalation, ingestion and dermal contact and partitions rapidly and equally throughout the organism in relation to the water content of organs and tissues. A small amount is excreted unchanged by the lungs and kidneys. Half-lives of methanol in the body are roughly 2.5 to 3 hours at doses less than 100 mg/kg bw. At high doses, disproportionate increases of the parent compound in blood are obtained in rodents, but not in humans. On the other hand, in humans, the metabolite formate accumulates at high doses. This important difference mirrors the different enzymes and enzyme capacities involved in the oxidative pathway from methanol to carbon dioxide. Specifically, two different rate-limiting processes have been identified: in rodents, high doses (after inhalation of 2.5 – 3.3 mg/L) lead to the saturation of catalase, resulting in the accumulation of methanol whereas formate levels remain low, whereas in primates (especially humans), the parent compound is well oxidized and does not accumulate, but formate increases disproportionately.
From studies in humans and monkeys exposed to concentrations of 0.26 – 2.6 mg/L (administered for 6 to 8 hours), it can be concluded that methanol remains close to 50 mg/L in blood. At inhalation exposures of 2.6 mg/L, rats also exhibit methanol blood levels that are not much higher (at about 80 mg/L), whereas the level in mice was 400 mg/L. At a higher inhalation exposure (6.5 mg/L), humans show the lowest blood methanol level (at 140 mg/L), followed by monkeys, rats, and mice, with the level in mice being more than 10 times higher than humans. Formate accumulation in primates has been observed at methanol doses greater than 500 mg/kg bw.
The corresponding dose levels for potassium methanolate that would lead to accumulation of formate in primates would be 1000 mg/kg bw. Such a dose level is already in the acutely toxic dose range. The methanol dose that saturates the folate pathway in humans is estimated to be 210 mg/kg bw, which corresponds to potassium methanolate doses of ca. 460 mg/kg bw. Due to the corrosive nature of the potassium methanolate, it is unlikely that exposure to potassium methanolate could result in an uptake of toxic doses of methanol.
References not included as study summaries in IUCLID:
OECD SIDS Initial Assessment Report for SIAM 22 (2006): Category of Methanolates: Sodium Methanolate, Potassium Methanolate (CAS No: Sodium Methanolate: 124-41-4; Potassium Methanolate: 865-33-8).
OECD SIDS Initial Assessment Report for SIAM 13 (2002): Potassium Hydroxide (CAS No: 1310-58-3).
OECD SIDS Initial Assessment Report for SIAM 19 (2004): Methanol (CAS No: 67-56-1).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.